Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03811444 · ClinicalTrials.gov registry record · NA
Simulated Clinical Use Testing On Safety Lancets (Test B)
A NA study, sponsored by HTL-Strefa S.A..
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT03811444: Completed NA study, sponsored by HTL-Strefa S.A..
NCT03811444 is a NA study that has completed, run by HTL-Strefa S.A.. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03811444, a NA study, has completed, sponsored by HTL-Strefa S.A..
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
A simulated clinical use testing on the HTL-Strefa's safety lancets
Interventions
- DEVICE Haemolance Plus safety lancet
- DEVICE Prolance safety lancet
- DEVICE MediSafe Solo safety lancet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-11-30 |
| Est. Completion | 2018-12-13 |
| Phase | NA |
What the finished NCT03811444 record still lists
NCT03811444 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Haemolance Plus safety lancet is the first listed.
NCT03811444 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03811444 about?
NCT03811444 is a clinical study titled "Simulated Clinical Use Testing On Safety Lancets (Test B)". A simulated clinical use testing on the HTL-Strefa's safety lancets
What is the current status of trial NCT03811444?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2018-11-30. Estimated completion is 2018-12-13.
What interventions are being tested in trial NCT03811444?
The interventions under investigation include: Haemolance Plus safety lancet (DEVICE), Prolance safety lancet (DEVICE), MediSafe Solo safety lancet (DEVICE).
Who is sponsoring clinical trial NCT03811444?
This trial is sponsored by HTL-Strefa S.A., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03811444's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI